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Abstract 
Purpose 
To investigate the correlation between the expression of Epidermal Growth Factor receptor 
(EGFr) and the reduction of the effective doubling time (TD) during radiotherapy treatment 
and also to determine the dose per fraction to be taken into account when the overall 
treatment time (OTT) is reduced in accelerated radiotherapy of head and neck squamous cell 
carcinoma (HNSCC). 
Methods 
A survey of the published papers comparing 3-years of local regional control rate (LCR) for a 
total of 2162 patients treated with conventional and accelerated radiotherapy and with a 
pretreatment assessment of EGFr expression, was made. Different values of TD were obtained 
by a model incorporating the overall time corrected biologically effective dose (BED) and a 
3-year clinical LCR for high and low EGFr groups of patients (HEGFr and LEGFr), respectively. 
By obtaining the TD from the above analysis and the sub-sites’ potential doubling time (Tpot) 
from flow cytometry and immunohistochemical methods, we were able to estimate the 
average TD for each sub-site included in the analysis. Moreover, the dose that would be 
required to offset the modified proliferation occurring in one day (Dprolif), was estimated. 
Results 
The averages of TD were 77 (27-90)95% days in LEGFr and 8.8 (7.3-11.0)95% days in HEGFr, if an 
onset of accelerated proliferation TK at day 21 was assumed. The correspondent HEGFr sub-
sites’ TD were 5.9 (6.6), 5.9 (6.6), 4.6 (6.1), 14.3 (12.9) days, with respect to literature 
immunohistochemical (flow cytometry) data of Tpot for Oral-Cavity, Oro-pharynx, Hypo-
pharynx, and Larynx respectively. The Dprolif for the HEGFr groups were 0.33 (0.29), 0.33 
(0.29), 0.42 (0.31), 0.14 (0.15) Gy/day if α = 0.3 Gy-1 and α/β = 10 Gy were assumed. 
Conclusions 
A higher expression of the EGFr leads to enhanced proliferation. This study allowed to 
quantify the extent of the effect which EGFr expression has in terms of reduced TD and Dprolif 
for each head and neck sub-site. 
Keywords 
EGFr, Doubling time, Potential doubling time, Cell loss factor 
Background 
HNSCC accelerates the production of clonogenic cells during radiotherapy, whereby an 
amount of a given dose of radiation may be used to sterilize cells produced during the 
treatment [1]. Therefore, by maintaining the same total dose, a reduction of OTT results in 
increased T-site control. 
The benefit of reduced OTT has been tested in several studies comparing conventional 
treatment with accelerated fractionation schedules. The data showed an improved 5-year LCR 
[2,3]. 
However, the response is heterogeneous with respect to the different expressions of EGFr in 
the patient population and also to the sub-sites, as accelerated repopulation of clonogenic 
tumour cells and locoregional control could arise. 
EGFr is overexpressed in the majority of HNSCC [4] and activation of the receptor leads to 
phosphorylation of the tyrosine kinase domains on the intracellular part of the receptor, 
activating downstream cascades which result in altered gene activation and modulation of the 
cell products. This has been related to increased cell proliferation, decreased apoptotic 
activity, increased angiogenesis, increased invasive and metastatic potential, and hence 
increased resistance to anti tumour therapy. 
Furthermore, it has been shown that tumours with high expression of EGFr have a better LCR 
when treated with accelerated radiotherapy, while there was no benefit of acceleration in 
tumours with low EGFr. 
Consequently, high EGFr has been suggested as a negative prognostic factor when OTT is 
prolonged, and as a positive prognostic factor when treatment time is reduced [5]. 
The aim of the present study is to investigate the correlation between EGFr expression and 
the reduction of TD during radiotherapy treatment and also to determine the dose per fraction 
to be taken into account when the OTT is reduced in accelerated radiotherapy of HNSCC. 
To achieve this goal, the data published in the literature were reviewed and analyzed by 
comparing different 3-year LCR and OTT for various dose fractionation schemes, also taking 
into account different sub-sites of HNSCC. 
Methods 
Literature review 
The primary end point considered for the present analysis was LCR, defined as the 
probability of avoiding local regional recurrence of cancer at the primary tumour site (T) or 
nodal (N) position, within 3-years after the end of radiotherapy. 
A survey of the published papers comparing LCR for patients with HNSCC treated with 
conventional and accelerated radiotherapy, respectively, and with a pretreatment assessment 
of EGFr expression, was made [6-11]. 
In the published papers, different criteria of EGFr expression assessment according to the 
intensity of staining were used. EGFr expression was classified by the investigators, with 
several quantitative or semi-quantitative scoring systems, i.e., absent, minimal, moderate, or 
intense staining (Table 1). The main characteristics for selection were conventional and 
accelerated fractionations, different OTT, assessment of EGFr expression and LCR, as listed 
in Table 1. 
Table 1 Treatment characteristics of the selected group 
Author Fractionation OTT(days) SIH % SIL % LCRH LCRL HR S 
Eriksen AO a [6] 33x2Gy 66 SI ≥ 50 SI < 50 0.15 0.44 Y N 
Eriksen AO b [6] 33x2Gy 45 SI ≥ 50 SI < 50 0.64 0.55 Y N 
Eriksen AO c [6] 33x2Gy 38 SI ≥ 50 SI < 50 0.77 0.57 Y N 
Eriksen RO a [7] 33x2Gy 45 SI ≥ 50 SI < 50 0.57 0.63 Y N 
Eriksen RO b [7] 33x2Gy 38 SI ≥ 50 SI < 50 0.70 0.62 Y N 
Bentzen JCO a [8] 33x2Gy 45 SI ≥ 40 SI < 40 0.30 0.45 N N 
Bentzen JCO b [8] 36x1.5 Gy 12 SI ≥ 40 SI < 40 0.54 0.49 N N 
Suwinski IJROBP a [9] 35x1.8 Gy 47 SI ≥ 33 SI < 33 0.33 0.70 N Y 
Suwinski IJROBP b [9] 35x1.8 Gy 35 SI ≥ 33 SI < 33 0.58 0.73 N Y 
Smid IJROBP a [10] 25x2Gy + 5x2.5 Gy ~ 46 A/m M/I 0.69 0.65 N Y 
Smid IJROBP b [10] 25x2Gy + 5x2.5 Gy ~ 34 A/m M/I 0.91 0.68 N Y 
Chung IJROBP a [11] 35x2Gy 47 SI ≥ 80 SI < 80 0.36 0.61 N N 
Chung IJROBP b [11] 30x1.8 Gy + 12x1.5 Gy 38 SI ≥ 80 SI < 80 0.54 0.68 N N 
Abbreviations: SI = Staining Intensity cut-point; A/m = Absent/minimal; 
M/I = Moderate/Intense; HR = Hypoxic Radiosensitizer; S = Surgery. 
Only those studies which reported a median follow-up of at least 3-years were included in the 
analysis. Table 2 lists the main clinical characteristics of the patients, namely age, sex, 
primary site, T stage and N stage. Further clinical information are in the reviewed papers. 
Table 2 Clinical characteristics of the selected groups 
Author E1 E2 BE SU SM CH 
number of patients 209 803 304 148 165 533 
Sex % M 74.2 81.0 72.0 90.0 66.0 79.2 
F 25.8 19.0 28.0 10.0 34.0 20.8 
Primary site % Oral Cavity / 12.0 13.0 50.6 100.0 10.3 
Oropharynx / 52.5 28.0 / 60.4 
Hypopharynx / 12.0 / / 13.7 
Nasopharynx / / 3.0 / / / 
Larynx 100.0 35.5 44.0 49.4 / 15.6 
T stage % T1 6.0 67.0 3.0 26.1 2.0 5.8 
T2 37.0 42.0 25.0 27.6 
T3 35.0 33.0 33.0 73.9 28.0 37.1 
T4 22.0 22.0 35.0 29.3 
Tx / / / / / 0.2 
N stage % N0 65.0 65.0 63.0 33.8 26.0 21.8 
N1 35.0 35.0 18.0 66.2 16.0 18.6 
N2a 15.0 1.0 9.6 
N2b 39.0 17.8 
N2c 17.0 19.3 
N3 4.0 1.0 12.9 
Abbreviations: E1 = Eriksen-AO, E2 = Eriksen RO, BE = Bentzen JCO, SU = Suwinski 
IJROBP, SM = Smid IJROBP, CH = Chung IJROBP. 
Radiobiological analysis 
The tumour effects were evaluated by the overall time corrected BED as in eq. (1) 
  (1) 
where n is the number of fractions of size d in Gy, α and β are the linear quadratic 
coefficients of dose, T is the overall time, Tk is the onset time for accelerated proliferation and 
TD the effective doubling time. The first term in eq. (1) (the dosimetric component, see 
Appendix A), is affected by differences in EGFr expression because of modification to α and 
β parameters that describe the intrinsic and repair radiosensitivity of tumour types, 
respectively. We add the subscripts H and L to indicate high or low EGFr expression 
respectively (BEDH(d) or BEDL(d)). The second term (the temporal component, see Appendix 
A) is affected by differences in EGFr expression due to the presence of the α parameter (αH or 
αL) and TD (TDH or TDL). Superscripts S and F are specified to distinguish between 
conventional (S = Slow) and accelerated (F = Fast) fractionations, respectively. 
From BED we have the standard model of tumour control probability (TCP) using the linear-
quadratic model incorporating the Poisson’s low [12], 
  (2) 
where N = ρ·V (ρ = cell density and V = volume) represents the initial number of potential 
proliferating cells in the tumour. Therefore, the cell survival probability being 
S = exp(−α·BED), the TCP represents the probability of avoiding local recurrence [13] at total 
dose D = n·d whereby we write TCP = LCR. 
Moreoever, in order to analyze the effects of EGFr expression due to the change in the OTT, 
the papers chosen in the survey had the same dose per fraction and total dose but a different 
OTT. 
Thus, by taking the natural logarithms of eq. (2) written for fast and slow fractionations, 
dividing the resultant equations and by taking the natural logarithm again, we get 
  (3.a) 
for high EGFr expression group, and 
  (3.b) 
for low EGFr expression group (see Appendix A). 
This expedient allows to eliminates the dependence of findings from the choice of dose 
fractionation and from the estimated values of α and β. The equations (3.a) and (3.b) are also 
independent notwithstanding the assumption about number of cells N. The uncertainties 
arising from these assumptions strongly influences the results of the other models that depend 
on such parameters. Therefore, this is the main advantage of equations (3.a) and (3.b). 
In each of these equations appears only one unknown (the effective doubling time) for which, 
being in a linear form, they are suitable for an easy comparison between LCR due to different 
EGFr expression groups with different OTT. This assessment was done by evaluating the 
differences of angular coefficients (ln2/TDH vs ln2/TDL) from the correspondent regression 
lines obtained by LCR available in literature (Figure 1). For those papers, where in addition 
to differences of OTT there are also differences in terms of dose fractionation, the correction 
as described in Appendix B was done. 
Figure 1 Linear regressions for LEGFr group (diamonds) and HEGFr group (circles) with 
y = ln(lnLCRS/lnLCRF) and x = (TS-TF) (days). The higher angular coefficient of HEGFr 
group line demonstrate a reduction of effective doubling time with respect to LEGFr group 
(proportionality with the inverse of the effective doubling time). Sub-figures refer to a 
different onset of accelerated repopulation (a) Tk = 0, (b) Tk = 14, (c) Tk = 21, (d) Tk = 28 days. 
Error bars represent the 95% confidence intervals 
Furthermore, dividing equations (3.a) and (3.b), we also obtained the ratio of the actual 
doubling times between the HEGFr and LEGFr groups that allows a direct analysis of the EGFr 
effects (Figure 2) as follows 
Figure 2 Curves of TD obtained by varying Tk, for HEGFr (black) and LEGFr (gray) groups 
based on the immunohistochemistry (continuous) and flow cytometry (dashed) methods 
to estimate the sub-sites 
i
Tpot. Differences are shown for Oral-Cavity (a), Oropharynx (b), 
Hypopharynx (c) and Larynx (d) 
  (4) 
Clinical analysis 
The actual doubling times obtained from the above analysis, represent a weighted average of 
the doubling times from different sub-sites as oral cavity (18.2% of patients), oro-pharynx 
(30.3% of patients), hypo-pharynx (14.8% of patients), and larynx (36.4% of patients). 
These sub-sites contribute differently to the average TD because they have different Tpot . 
However, the TD for each sub-sites can be estimated if Tpot and is the cell loss factor (φ) are 
known as described by Steel [14]. In particular Tpot can be measured by a single biopsy 
withflow cytometry as well as immunohistochemistry techniques (Table 3). 
Table 3 Numerical results of sub-site 
TD (days) and Dprolif (Gy/day) for high EGFr expression group (<
i
Tpot > =5.2 days by flow cytometry; <
i
Tpot > =3.4 days by 
immunohistochemistry; TK = 21 days). The 
i
TD for each i sub-site (upper rows) is almost twice of 
i
Tpot by flow cytometry and more than double 
of 
i
Tpot by immunohistochemistry from literature (bottom rows) [15]. Consequently, a preclinical estimation of Dprolif by flow cytometry (left 
columns, bottom rows) or immunohistochemistry (right columns, bottom rows), results almost double and more than double if compared to the 
estimation of Dprolif obtained by mathematical model (left and right columns, upper rows), respectively. The 95 % confidence intervals are shown 
within the brackets. 
Abbreviations: 
i
Dp(0.25; 0.3; 0.35) = Dprolif calculated with α = 0.25, α = 0.3, α = 0.35 Gy
-1
 respectively, α/β = 10 Gy, d = 2 Gy 
Sub-site Number of 
patients 
 
Doubling 
time 
Flow Cytometric (FCM) Immunohistochemical (Hi) 
days Dp (0,25) Dp (0,3) Dp (0,35) days Dp (0,25) Dp (0,3) Dp (0,35) 
Oral Cavity 394 (18.2%) 
TD 6.6 (5.5-8.2) 0.35 (0.28-0.42) 0.29 (0.23-0.35) 0.25 (0.20-0.30) 5.9 (4.9-7.4) 0.39 (0.31-0.47) 0.33 (0.26-0.39) 0.28 (0.22-0.34) 
Tpot 3.9 0.59 0.49 0.42 2.3 1.00 0.84 0.72 
Oropharynx 655 (30.3%) 
TD 6.6 (5.5-8.2) 0.35 (0.28-0.42) 0.29 (0.23-0.35) 0.25 (0.20-0.30) 5.9 (4.9-7.4) 0.39 (0.31-0.47) 0.33 (0.26-0.39) 0.28 (0.22-0.34) 
Tpot 3.9 0.59 0.49 0.42 2.3 1.00 0.84 0.72 
Hypopharynx 320 (14.8%) 
TD 6.1 (5.1-7.6) 0.38 (0.30-0.45) 0.31 (0.25-0.38) 0.27 (0.22-0.32) 4.6 (3.9-5.8) 0.50 (0.40-0.59) 0.42 (0.33-0.49) 0.36 (0.28-0.42) 
Tpot 3.6 0.64 0.53 0.46 1.8 1.28 1.07 0.92 
Larynx 784 (36.3%) 
TD 12.9 (10.7-16.0) 0.18 (0.14-0.22) 0.15 (0.12-0.18) 0.13 (0.10-0.15) 14.3 (12.4-18.1) 0.16 (0.13-0.19) 0.14 (0.11-0.16) 0.12 (0.9-0.13) 
Tpot 7.6 0.30 0.25 0.46 5.6 0.41 0.34 0.29 
Therefore, the average cell loss factor was estimated using pretreatment data about Tpot 
available in literature [15,16], then the actual doubling time for each i sub-site (
i
TD) was 
obtained (see Appendix C). 
Moreover, from 
i
TD we also estimated the dose (in fractions of size d) that would be required 
to offset the effect of proliferation occurring in one day [17] by the follows equation 
ln 2i
prolif i
D
D
T a d
 (5) 
Statistical analysis 
In all the original studies of the survey the primary endpoint was LCR, 3 or 5-years after 
completion of radiotherapy, although only the 3-year LCR were extrapolated in order to 
compare the homogeneous parameters. LCR were assessed by the Kaplan-Meier method with 
a log rank test (statistical significance: p ≤ 0.05, two-sided). The LCR 95% confidence 
intervals are obtained by Greenwood’ formula [18]. Comparison between regression lines 
was done by Fisher’s exact test. 
Results 
Table 1 and 2 describe the main clinical characteristics and treatment parameters of the 
selected groups in the survey. 
Linear regression lines from equations (3.a) and (3.b), for HEGFr and LEGFr groups, are shown 
in Figure 1 with respect to different choices of the onset for accelerated repopulation (Tk). 
The significant distinction of the angular coefficients for different groups (p-values ≤ 0.02) 
correspond to an average TD of 77 days (27–90)95% for LEGFr and to an average of 8.8 days 
(7.3-11.0)95% for HEGFr, if an onset of accelerated proliferation TK at day 21 was assumed. 
In Figure 2 the significant HEGFr TD reduction with respect to LEGFr TD for each head and neck 
sub-site, are shown by varying TK. 
In Figure 3 the averages of Dprolif are shown based on the flow cytometry and 
immunohistochemical methods to estimate the sub-sites 
i
Tpot. The maximum value of Dprolif, 
up to about 0.5 Gy/day, is obtained corresponding to an onset of accelerated repopulation that 
starts from the fourth week (TK at about 28
th
 day). Sensitivity analysis is shown with respect 
to different values of α with α/β = 10 Gy. 
Figure 3 Curves of Dprolif obtained by varying Tk, for HEGFr (continuous) and LEGFr 
(dashed) groups based on the flow cytometry (left column) and immunohistochemistry 
(right column) methods to estimate the sub-sites 
i
Tpot. Sensitivity analysis is shown with 
respect to different values of α with α/β = 10 Gy: α = 0,25 Gy-1 (upper curves); α = 0,3 Gy-1 
(mean curves); α = 0,35 Gy-1 (bottom curves). Differences are shown for Oral-Cavity (a,b), 
Oropharynx (c,d), Hypopharynx (e,f) and Larynx (g,h) 
The weighted average potential doubling times < iTpot > of 5.2 days and 3.4 days [15,16] were 
obtained corresponding to averages for cell loss factors as < φ(FCM) > = 0.41 (0.29-0.52)95% 
and < φ(Hi) > = 0.61 (0.53-0.69)95% with respect to the flow cytometry and 
immunohistochemistry, respectively. 
Table 3 reports numerical results for each sub-site in HEGFr group with 
i
TD and 
i
Dprolif 
calculated for different values of α (α/β = 10 Gy). It may be noted that the iTD for each i sub-
site is almost twice of 
i
Tpot obtained by flow cytometry and more than double of 
i
Tpot obtained 
by immunohistochemistry. This means that a pre-treatment assessment of Dprolif by flow 
cytometry or immunohistochemistry may significantly overestimate the dose required to 
offset the accelerated proliferation occurring in one day. 
In Figure 4, the histogram of the ratio between TDL and TDH (eq. 4) shows an average 
reduction of about 7 times in average (6.6-8.3)95% for the HEGFr group with respect to the 
LEGFr. This ratio could have significant implications on the clinical management of these 
patient groups. In fact, while the HEGFr group would benefit from an increase of the 
dose/fraction (Hypo-fractionation) and the consequent reduction of OTT to compensate for 
the increase in the proliferation rate - corresponding to a reduced TD -, the LEGFr group does 
not require a reduction of OTT for which it would be more indicated a reduction of the 
dose/fraction (Hyper-fractionation) which would result in a reduced toxicity for all the organs 
at risk. 
Figure 4 Histogram of ratios between TD values in the LEGFr and HEGFr groups. The error 
bars represent the 95% confidence intervals while the overlay trend line represent the average 
of values. Abbreviations: E1 = Eriksen from AO, E2 = Eriksen RO, BE = Bentzen JCO, 
SU = Suwinski IJROBP, SM = Smid IJROBP, CH = Chung IJROBP 
Discussion 
In the recent years there has been a great interest to find factors that predict tumours suitable 
for accelerated radiotherapy and considerable interest has been given to cell kinetic 
parameters such as the Tpot. Since regeneration and tumour cell proliferation are mechanisms 
at the cellular level, particular attention has been focused on identifying the specific cellular 
characteristics, such as variations in EGFr expression. The latter is an important mediator of 
cell growth and its over-expression has been associated with tumour progression and poor 
survival in many solid cancers. Several studies have demonstrate the potential of EGFr as a 
predictive and prognostic marker in radiotherapy for HNSCC [19]. 
In the present study a direct demonstration of the link between EGFr status and the time 
factor in fractionated radiotherapy, has been made. All the clinical studies surveyed, from the 
available literature, had a random allocation for “reduced” or “conventional” OTT and 
demonstrated an increase in LCR when the OTT was reduced. 
Unfortunately, OTT reduction yields clinical benefits in terms of LCR but could worsen the 
radiation-induced acute side effects which need to be carefully evaluated using appropriate 
radiobiological models [20]. 
Moreover, some studies also demonstrated that tumours with high EGFr respond better to the 
reduction of the OTT compared to low EGFr tumours [6,7,9]. The response was 
heterogeneous if referring to the sub-sites included in the analysis. 
Therefore, our intent was to evaluate the extent of accelerated proliferation due to an EGFr 
over-expression, in terms of reduced actual doubling time as well as required dose to offset 
the effect of proliferation occurring in one day. 
To obtain these results no assumption was made with the exception of the validity of a linear 
quadratic and TCP model. Therefore, the fact that the EGFr expression changes the 
radiosensitivity and the proliferation rate of the cells, has to be necessarily included in these 
models as a variation of the parameters (α, β and TD ) describing them. 
Although in all the studies selected for the survey, the accelerated repopulation of tumour 
cells during radiotherapy was suggested as an important cause of treatment failure, the main 
difficulty in our analysis was that head and neck cancer represents a heterogeneous group of 
cancers and the benefit is not act equal for the different tumours. We also attempted to 
estimate these differences. 
We are aware that an important drawback in the analysis is to be found the differences among 
treatment modalities. Some studies have included radiotherapy alone, others postoperative 
radiotherapy, others the use of radio-sensitizing hypoxic drugs. We therefore stress the 
versatility and enormous potential of the method we propose. 
Indeed, the relationship between elements representative of the radiation effects calculated 
only on groups of patients who undergo the same treatment, is based accordingly. In other 
words, although radiotherapy alone is profoundly different from postoperative radiotherapy 
or from radiotherapy combined with radio-sensitizing drugs, the relationship of the effects 
calculated within the same type of therapy, nullify these contributions, allowing to obtain 
only those due to the different expression of EGFr. 
The validity of this statement is confirmed by the very low dispersion of data around the 
linear regression lines obtained from them. Our results clearly demonstrate proportionality 
between differences in treatment duration and correspondent ratios of LCR (the latter in 
logarithmic form). This strong linearity allowed us to quantify the reduction of actual 
doubling time of the HEGFr group with respect to the LEGFr group. 
Unfortunately, in the papers, different definitions for the level of cut-points of EGFr 
expression were used. In some studies a cut-point of 50% was chosen as being objective and 
reproducible, others fixed a cut-point of 33%, 40%, 80%, etc. However, it is obvious that no 
dichotomous division between high and low EGFr tumour expression exist and a continuous 
variable must apply. In addition, because samples for the various studies were collected from 
various pathology departments and staining intensity can be dependent on tissue fixation 
[21], the evaluation of staining intensity was not entirely homogeneous. This was certainly 
the greatest source of approximation in the quantitative results obtained. 
Despite these limitations, our results indicate a clear reduction of effective doubling time TD 
in HEGFr with respect to the LEGFr groups. This reduction did not so excessive as the necessary 
to reach the minimum value which is represented by Tpot (that is the limit where the cell loss 
fraction is reduced to zero and the proliferation is fastest). 
We consider this result very important, especially because an accurate estimate of TD allows 
to obtain the equivalent dose for accelerated repopulation that is essential to making rational 
adjustments to the overall dose when the overall time is increased. This has become more 
than just an academic question in the area of IMRT when, instead of using shrinking field 
techniques, radiation oncologists commonly use a differential dose per fraction to deliver 
graded doses in the same overall treatment time. 
Our results consisted of Dprolif systematically lower than those accepted in the literature that 
are often obtained through an evaluation of-the potential doubling time, which is a 
characteristic of each proliferative cell, and not through the effective doubling time, which is-
a characteristic of a group of cells [22]. 
In the case of oropharynx, for example, we obtained values up to 0.39 Gy/day (0.31-0.47)95% 
while in the literature we have values between 0.48-0.68 Gy/day [23,24]. For the larynx we 
obtained values up to 0.16 Gy/day (0.13-0.19)95%, while other estimates for this tumour are 
between 0.3 and 0.5 Gy/day [17]. Only in the case of hypopharynx we had values greater 
than 0,5 Gy/day (0.40-0.59)95%. 
The difference can partly be explained by the heterogeneous behavior of the different sub-
sites involved in our analysis (a specific sub-site clinical study could discriminate more finely 
between different contributions). However, our opinion is mainly based on the interpretation 
of the correlation between TD and Tpot. 
As a first hypothesis, the reduction of TD can be easily explained with a correspondent 
reduction of Tpot, but clinical data has shown that for patients with short Tpot (fast tumours) 
there was no statistically significant trend to do worse [25]. Moreover, we found a reduction 
of TD with an average factor of about 7 in the HEGFr with respect to the LEGFr group, and the 
same extent was never found by measures that assess Tpot from biopsy among patients. 
Consequently, given that a shorter TD may also result from a reduced φ after the beginning of 
treatment (see Appendix C), our results suggest that the latter possibility is favored. In this 
case, the tendency of φ toward zero, indicates a reduction of the clonogen doubling time TD 
until it equals the pretreatment Tpot. Hence, our results for TD can be easily explained from an 
incomplete reduction of φ toward zero. 
Furthermore, a φ reduction being associated with a low differentiation, would correspond to 
an increase in a non-differentiated component. 
Thus, the question arises about how two different results may be reconciled. 
On one hand, the simultaneous expression of a differentiated pattern and high levels of EGFr 
display a higher degree of accelerated repopulation compared to carcinomas with low levels 
of EGFr or poor differentiation [5]. On the other hand, as is clear from the Steel’s formula, 
the reduction of TD is due to a reduction of the differentiation levels. 
A possible explanation could be that two different levels of differentiation may coexist 
locally. 
This hypothesis is based on the clinical observation that high levels of EGFr expression were 
found to be more pronounced at the tumour borders compared to the central parts of the 
tumour tissue (p < 0.0001) [6]. Therefore, on the border of the tumour, the EGFr over-
expression would be compatible with a low level of differentiation and rapid tumour growth 
(as from Steel’s formula). In more central tumour areas, the low EGFr expression may be 
compatible with a high level of differentiation and reduced tumour cell proliferation. This 
spatial non-uniformity, suggests that the precise location of biopsy sampling and a 
subsequent classification of tumours (high or low EGFr and level of differentiation) are 
crucial. A such hypothesis, of course, requires further investigation in clinical studies. 
Conclusion 
Increased expression of the EGFr can lead to enhanced proliferation which can be 
countervailed by reducing the time available for tumour cell proliferation, thereby reducing 
the overall treatment time. In this case, the impact of high EGFr expression changes from 
being a negative to a positive prognostic value in terms of local control rate. 
In this study we introduced a model that allows to quantify the influence of EGFr expression 
in terms of reduced doubling time during the treatment and also the dose per fraction to be 
taken into account when the overall treatment time is reduced in accelerated radiotherapy. 
Furthermore, using this model, we can also estimate the parameters inherent in different sub-
sites which may identify the optimal dose fractionation regime more likely to benefit these 
sub-sets of patients. 
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Appendix A. Appendix A 
To simplify the radiobiological analysis, eq. (1) can be rewritten by considering the BED as 
the difference between a dosimetric and a temporal component: 
  
 
The BED(d) for high EGFr expression group, for instance, is 
  
 
while the BED(T) for the same group is 
  
 
Thus, to take into account the differences of radiosensitivity as well as OTT, two and four 
possible expressions of BED(d) and BED(T) are considered, respectively: 
  
 
For different EGFr expressions and OTT we have also 
  
 
where, for example 
  
 
Therefore, by taking the natural logarithms of this expression and dividing it for the same 
expression with a different OTT, we can nullify the contributions of ρ·V and BED(d) – 
because of the same fractionation – obtaining only those due to the different expression of 
EGFr with respect to the OTT. 
For the high EGFr expression group, for instance, we have 
  
 
from which, by taking the natural logarithms again, we have eq. (3.a). The same procedure 
leads to eq. (3.b). 
Appendix B. Appendix B 
The equations (3.a) and (3.b) are valid if the hypothesis of equal dosimetric component of 
BED in conventional and accelerated fractionation, is valid. However, this is not true for all 
the papers in the literature surveyed. The differences in terms of dose fractionation were 
corrected using the follows 
   
where the indexes nc and c stand for “non-corrected” and “corrected”, respectively. BEDS(d) 
and BED
F
(d) refer to different BED dosimetric components in conventional and accelerated 
fractionation, respectively. The exponential factor incorporates the difference of BED only 
due to the dosimetric BED component, and therefore enables the contribution to be corrected, 
thanks to this component. 
Appendix C. Appendix C 
In order to estimate the actual doubling time for each sub-site in the analysis, different 
potential doubling times Tpot were considered from literature [15]. 
The latter has been introduced by Steel as the clonogen doubling time that would be 
measured if cell loss was ignored, i.e. if both daughter cells remained clonogenic after mitosis 
[14]. 
In practice clonogens are lost through many possible mechanisms, including differentiation, 
death, and metastasis, and the net result is that TD will be longer than Tpot. 
Steel’s formula can be written as follows: 
  
 
wherein φ is the cell loss factor. This equation shows that TD can be calculated if Tpot and φ 
are known. 
In particular Tpot can be measured by a single biopsy using flow cytometry or 
immunohistochemistry techniques, while the average cell loss factor < φ > was obtained in our 
analysis taking the average potential doubling time weighted on percentages for any sub-site 
(<
i
Tpot > =∑i pi·
i
Tpot with i = 1,..,4 and p1 = 21% for oral cavity, p2 = 20% for oro-pharynx, 
p3 = 17% for hypo-pharynx and p4 = 42% for larynx), by the follows 
  
 
The actual doubling time for each i sub-site, was then obtained as follows 
1
i
poti
D
T
T
 
 
Results were reported in Table 3. 
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